Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a gadolinium‑based contrast agent presented as a sterile injectable solution for intravascular use. It enhances magnetic resonance imaging to help visualize vascular structures and tissue pathology in adult and pediatric patients. GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and diagnostic imaging centres worldwide.

GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and diagnostic imaging centres worldwide.

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve the visualization of various anatomical regions and disease processes.

- Central nervous system imaging: improves the detection of lesions, tumors, and vascular malformations. - Cardiovascular imaging: enhances visualization of cardiac chambers, vessels, and myocardial perfusion. - Abdominal and pelvic imaging: clarifies organ structure and helps identify lesions in liver, kidneys, and other viscera. - Whole‑body screening: aids in the detection of metastatic disease and systemic pathology. - Vascular angiography: provides high‑resolution images of arteries and veins for interventional planning.

Adverse reactions to gadodiamide‑based contrast agents are generally uncommon but can range from mild to severe.

Common Side Effects: - Nausea: mild, transient episodes reported by some patients. - Headache: occasional brief discomfort following injection. - Injection site discomfort: mild pain or erythema at the site of administration. - Warmth or flushing: transient sensation during or shortly after injection. - Metallic taste: brief metallic sensation in the mouth.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment. - Anaphylactoid reactions: hives, bronchospasm, or hypotension requiring emergency care. - Severe allergic reaction: angio‑edema or anaphylaxis. - Cardiac arrest: extremely rare but reported in hypersensitive individuals. - Renal toxicity: worsening kidney function in susceptible patients.

When using Omniscan, clinicians should assess patient history and renal function, and follow recommended safety measures.

- Renal assessment: evaluate glomerular filtration rate before administration. - Hydration: ensure adequate patient hydration to facilitate gadolinium elimination. - Allergy history: screen for prior reactions to contrast media. - Pregnancy: avoid use unless clearly needed, as fetal safety data are limited. - Pediatric use: adjust dosing according to weight and monitor closely. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Omniscan may interact with other agents that affect renal function or provoke hypersensitivity.

Major Interactions (Avoid): - Nephrotoxic drugs: concurrent use with high‑dose aminoglycosides or IV contrast iodine may increase renal risk. - Immunosuppressants: heightened risk of severe allergic reactions when combined with biologic agents.

Moderate Interactions (Monitor Closely): - Diuretics: may alter renal clearance of gadodiamide, requiring monitoring of kidney function. - Metformin: assess renal function and consider temporary discontinuation to prevent lactic acidosis. - ACE inhibitors/ARBs: monitor for additive effects on renal perfusion. - NSAIDs: may compound renal stress, especially in patients with pre‑existing kidney disease. - Calcium channel blockers: no direct interaction but monitor blood pressure changes during imaging procedures.